Neural histology reveals NASH treatment-response signals missed by ordinal staging
Source check: Source checked. Not independent scientific confirmation.
Finding: Neural biopsy analysis quantified heterogeneous fibrosis in NASH trials. A threshold derived from STELLAR data identified fibrosis responses in 27% of 63 cilofexor-plus-firsocostat recipients versus 5% of 37 placebo recipients in ATLAS, where manual staging did not show a significant difference. This retrospective secondary analysis does not reverse the original trial endpoint or establish clinical treatment benefit; findings depend on the selected response threshold.
Technology: Deep convolutional neural network; DELTA Liver Fibrosis score
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Residual/inception-inspired CNNs quantify pixel-level fibrosis patterns; a distribution-change score measures treatment-associated tissue changes.
- Test and result
- Patient-separated histology development/testing, an ATLAS-only test cohort and retrospective treatment-response/clinical-progression analyses.
- Limitation / still unknown
- Prospective endpoint validation and clinical outcome benefit remain unestablished; significance depends on the response threshold and post-hoc analysis.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8361999/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Primary relevant Methods/results/limitations, exact primary front identity and current primary PubMed notice metadata; version dates distinguished..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.